Full Press Release Details
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting.
LXRX
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Key Takeaway: New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
Price reaction · baseline $1.11 (2023-10-27 close) · 3 other LXRX headline(s) in the window, move may be shared
day 0 close
+8.1%
day 1
+11.7%
day 3 · peak
+26.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus